Diagnosis and treatment of pancreatic cancer: an expert opinion from the 9th CECOG Pancreas Cancer Academy

Read full text Summarise with VIRAT
Authors: Michel Pierre Ducreux, Thilo Hackert, Teresa Mercade Macarulla, Davide Melisi, Mariano Ponz‐Sarvisé, Gerald W. Prager, Helmut Ringl, Julien Taïeb, A Vogel, Harpreet Singh Wasan, Christiane Thallinger, C. Zielinski
Cited by: 0
References: 69

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Summary Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging malignancies, with a dismal prognosis and limited therapeutic options. The 9th CECOG Pancreas Cancer Academy brought together leading international experts to review recent advances and establish a consolidated expert opinion on the biology, diagnosis, and treatment of pancreatic cancer. Pancreatic ductal adenocarcinoma is characterized by extensive molecular heterogeneity, with KRAS mutations being the primary driver of most cases. Diagnosis relies on a multimodal imaging approach, while molecular diagnostics are increasingly essential for identifying actionable biomarkers and understanding resistance mechanisms. Multidisciplinary tumor boards are crucial for addressing all aspects of diagnosis and treatment. Treatment strategies are tailored to disease stage and patient performance status. For resectable disease, upfront surgery followed by adjuvant chemotherapy (preferably mFOLFIRINOX) remains the standard, although neoadjuvant therapy is gaining importance for borderline resectable tumors. In metastatic disease, FOLFIRINOX, NALIRIFOX, and gemcitabine–nab-paclitaxel are first-line options. Second-line therapies focus on switching drug classes and tailoring therapies according to patient fitness. Novel therapies, including targeted agents, immunotherapies, and antibody–drug conjugates, are currently being assessed in clinical trials. Despite progress, the complexity of pancreatic cancer demands continued research into biologically driven treatments and early detection strategies to improve patient survival and quality of life.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Pancreatitis Pathology and Treatment Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
memo - Magazine of European Medical Oncology
Volume
19
Issue
2
Pages
96–106
Publication date
27 March 2026
Language
EN